Home / Health / Millions Use GLP-1s: Cost a Major Barrier
Millions Use GLP-1s: Cost a Major Barrier
4 Mar
Summary
- About three million Canadian adults use GLP-1 drugs.
- Many Canadians interested in GLP-1s face cost barriers.
- GLP-1 use affects spending on food and other goods.
An estimated three million Canadian adults are presently using GLP-1 medications such as Ozempic, according to a new survey. Millions more Canadians express interest in these drugs but find the cost prohibitive. The survey reveals that over half of GLP-1 users report a decreased appetite, and 40% notice fewer food cravings.
These changes are reshaping consumer behavior, with about 30% of GLP-1 users dining out less frequently. Many are also purchasing more fresh produce and protein. While weight loss is the primary driver for GLP-1 use, diabetes management and heart health are also significant reasons. Men are more likely than women to cite heart health benefits.
In the U.S., GLP-1 usage is even higher, with 11% of surveyed Americans taking the medication. Cost and insurance coverage remain key concerns for Canadians interested in starting GLP-1s. Beyond food expenses, users are also reporting increased spending on clothing, personal care, and fitness.
Concerns about side effects and high out-of-pocket costs, sometimes hundreds of dollars monthly, are barriers for many. While some receive full insurance coverage, a significant portion pays entirely out-of-pocket, highlighting the accessibility challenges for these widely used medications.
